Combination therapy treatment for viral infections

599128 Disclosed is a pharmaceutical composition comprising an EP4 receptor agonist and an antiviral agent, in a single dosage form, with one or more pharmaceutically acceptable excipients wherein at least one of the EP4 receptor agonist and the antiviral agent is in an amount that is below the optimal dosage to treat the same viral disease when the antiviral agent or EP4 receptor agonist is used alone, where said EP4 receptor agonist is selected from the group consisting of beraprost, nileprost and so on and said antiviral agent is selected from the group consisting of oseltamivir, zanamivir, peramivir, and { (4S,5R,6R)-5-acetamido-4-guanidino-6- [(1R,2R)-2-hydroxy-1-methoxy-3-(octanoyloxy)propyl]-5,6-dihydro-4H-pyran-2-carboxylic acid.